Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 16/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | FPR3 | P25089 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | GPR183 | P32249 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | P2RY13 | Q9BPV8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2130983 | 1.00 | P2RY12 (0.49) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL4950559 | 1.00 | P2RY12 (0.49) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL2612406 | 1.00 | P2RY12 (0.49) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL2412436 | 1.00 | P2RY12 (0.49) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL16800339 | 0.94 | P2RY12 (0.42) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL13192687 | 0.92 | P2RY12 (0.47) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL13192763 | 0.92 | P2RY12 (0.47) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL26532131 | 0.91 | P2RY12 (0.39) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL19445332 | 0.90 | P2RY12 (0.40) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL14900250 | 0.90 | P2RY12 (0.49) | P2RY12PGRADORA3CHRM1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9604991-B2 | Preparation method of ticagrelor and intermediates thereof | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2017-03-28 | — | — | US | disclosed |
| US-20160102101-A1 | Preparation method of Ticagrelor and intermediates thereof | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2016-04-14 | — | — | US | disclosed |
| WO-2016030704-A1 | SOLID FORM OF INTERMEDIATE OF TICAGRELOR | CIPLA LIMITED (IN) | 2016-03-03 | — | — | WO | disclosed |
| WO-2014102830-A1 | A PROCESS FOR PREPARATION OF TICAGRELOR AND INTERMEDIATES THEREOF | MEGAFINE PHARMA (P) LTD. (IN) | 2014-07-03 | — | — | WO | disclosed |
| US-7381828-B2 | Triazolo pyrimidine compounds | AstraZēneca AB (SE) | 2008-06-03 | — | — | US | disclosed |
| US-20070049755-A1 | Novel triazolo pyrimidine compounds | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049755-A1 | Novel triazolo pyrimidine compounds | TYMS, TYMP, DPYD | P2RY12 191/4885PGR 2439/4885ADORA3 320/4885 |
| US-20160102101-A1 | Preparation method of Ticagrelor and intermediates thereof | TPMT, NUDT1, ITPA | P2RY12 66/4885PGR 1972/4885ADORA3 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.